A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective. The emerging roles of HDACs in DNA repair provide new opportunities for improving tradi...
Main Authors: | Hemann, Michael, Liu, Chuan, Ding, Hongyu, Li, Xiaoxi, Pallasch, Christian, Hong, Liya, Guo, Dianwu, Chen, Yi, Wang, Difei, Wang, Wei, Wang, Yajie, Jiang, Hai, 1979- |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | en_US |
Published: |
Wiley Blackwell
2015
|
Online Access: | http://hdl.handle.net/1721.1/97593 |
Similar Items
-
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
by: Raffaella Cincinelli, et al.
Published: (2018-01-01) -
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
by: Jasmine M. Cross, et al.
Published: (2020-05-01) -
Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression.
by: Wang, Z, et al.
Published: (2010) -
Signal stability of Cy3 and Cy5 on antibody microarrays
by: Kim Caroline, et al.
Published: (2006-10-01) -
STRUCTURE MODIFICATION OF ANDROGRAPHOLIDE TO IMPROVE ITS POTENCY AS ANTICANCER
by: Hadi Poerwono, et al.
Published: (2010-06-01)